Kovina Therapeutics

Kovina Therapeutics is pioneering a novel antiviral approach to address the significant unmet medical need in HPV-associated diseases, from precancerous lesions to invasive cancers. Its core technology involves small molecules that selectively inactivate the HPV E6 oncoprotein, triggering apoptosis in infected cells while sparing healthy tissue. The company is backed by NIH grants and a seasoned leadership team, positioning it to develop a non-surgical treatment option for a global patient population underserved by current vaccines and standard therapies.

First-in-class small molecule inhibitors designed to selectively target and inactivate the HPV E6 oncoprotein, restoring p53 function and triggering apoptosis specifically in HPV-infected cells.

The competitive landscape for HPV therapeutics includes companies developing therapeutic vaccines, immune checkpoint inhibitors, and other immunotherapies. However, Kovina's approach of directly targeting the viral E6 oncoprotein with a small molecule is a distinct and novel mechanism. It would compete with standard-of-care procedures (surgery, radiation) for precancerous lesions and with systemic therapies for cancers, aiming to offer a more targeted and potentially less toxic alternative.